On the 23th of July, the Brazilian Instituto Nacional da Propriedade Industrial (INPI) opened a debate regarding the criteria of patentability in the field of medicines. The meeting was attended by ALANAC (National Association of Pharmaceutical Laboratories), ABIFINA (Brazilian Association of Industries of Fine Chemistry, Biotechnology and their Specialties), FIOCRUZ (Institution for Research and Development in Biomedical Sciences – Rio de Janeiro, Brazil), and UFRJ (Universidade Federal do Rio de Janeiro ). Also, representatives of national laboratories attended the debate.
Let’s wait and see if something comes out from this debate.
Welcome to IPTango
Popular Posts | Last 30 days
-
The World Intellectual Property Organization (WIPO) will hold the Tenth Session of the WIPO Conversation on Intellectual Property and Front... -
En Colombia el Tribunal Superior de Barranquilla le dio la razón al escritor Gabriel García Márquez (Premio Nobel de Literatura, 1982) en un... -
Ayer se anunció la publicación de la 17ª edición del Índice Mundial de Innovación ( GII , por sus siglas en inglés). Publicado desde 2007, ... -
Roberto Gómez Bolaños , creador de los famosos personajes como ‘El Chavo del 8’ y ‘El Chapulín Colorado”, falleció el pasado 28 de noviembre... -
From Brazil we looked at the number ‘57’ as a registered Geographical Indication (GI). The application came from the Instituto Bordado Filé ...
-
El Tribunal Superior de Justicia de Ciudad de México determinó que Eduardo Moreno Laparade, sobrino de Cantinflas, es el "único y le...
-
The official theme of the 2010 South African World Cup is under debate. The singer and songwriter, Wilfrido Vargas, accused Shakira of plagi... -
El pasado 10 de diciembre de 2013 se celebraron los primeros 20 años del Instituto Mexicano de la Propiedad Industrial ( IMPI ). El IMPI ... -
Since this weblog has just touched upon the subject of trade mark coexistence agreements (in Peru), it is relevant to add that this very to... -
WHAT'S GOING ON THIS WEEK? The European Patent Office ( EPO ) and the European Union Intellectual Property Office ( EUIPO ) ar...
Approved by the IPKat
IPTango is an approved blog by the IPKat
Creative Commons (CC BY-NC)
IPTango licenses the use of this blog posts under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). IPTango autoriza el uso de las publicaciones de este blog bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional (CC BY-NC).
2 comments
Write commentsdo you know what the substance of the discussion/debate was?
ReplyThe INPI web page only disclosed that the debate was regarding the ‘criteria for patentability'. I cannot elaborate more on that, however my guess – and I will be speculating, is that the discussion could have been in: pipeline system and/or the double examination on the same invention when ANVISA intervenes (this issue has brought contradictory decisions). As soon as we get more in-depth info on this, it will be posted – and if some of our readers know or have more facts, we will like to hear from them.
ReplyIn general I think that the pharma patent in Brazil has always been controversial and so, any debate and discussion from different sectors is always welcome.